GastroenterologyTargeting NEK7-Mediated EGFR Phosphorylation to Overcome Lenvatinib Resistance in Hepatocellular Carcinoma
MedXY Editorial Team
Highlight
- NEK7 identified as a key driver of acquired lenvatinib resistance in hepatocellular carcinoma (HCC).
- NEK7 phosphorylates endothelial growth factor receptor (EGFR) specifically at serine 1070, activating downstream MAPK and PI3K/AKT pathways.
- Inhibitory peptides targeting the EGFR domain responsible for NEK7-mediated phosphorylation successfully suppress lenvatinib resistance in HCC models.
- Targeting the NEK7-EGFR interaction offers a novel therapeutic strategy to overcome treatment resistance in advanced HCC.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
